Communiqués Johnson & Johnson

Actions

JNJ

US4781601046

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:23:54 22/07/2026			Varia. 5j.	Varia. 1 janv.
254,65 ^USD	+1,61%		+3,19%	+23,17%

16:14	J&J obtient le feu vert de la FDA pour son système de chirurgie robotisé
14:36	Johnson & Johnson reçoit l'autorisation de mise sur le marché de la FDA pour son système de chirurgie robotique Ottava	CI

Communiqués

13:01	Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System	BU
21/07	A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening	PR
17/07	Johnson & Johnson : Second Quarter 2026 2026 Second-Quarter Earnings Transcript	PU
16/07	Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award	BU
16/07	Johnson & Johnson : Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award	PU
16/07	DePuy Synthes Acquires Expanding Innovations™	BU
15/07	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026	BU
15/07	Johnson & Johnson reports Q2 2026 results, raises 2026 outlook	BU
09/07	Delhi High Court Grants ₹3.34 Crore Damages To Johnson & Johnson In Counterfeit Medical Devices Case	AQ
08/07	Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform	BU
29/06	Johnson & Johnson : DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer	PU
26/06	Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis	PR
26/06	Johnson & Johnson : CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma	PU
19/06	Johnson & Johnson : Highlights Positive Results from MEMBRANE Trial Published in JAMA Neurology	PU
15/06	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida	BU
13/06	New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma	PR
12/06	Johnson & Johnson - IMAAVY demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia, an autoantibody-driven disease	AQ
11/06	Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients	BU
11/06	IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies	PR
09/06	Johnson & Johnson : DePuy Synthes Launches VELYS™ Hip Navigation with AI to Support Intraoperative Consistency and Efficiency in Total Hip Arthroplasty	PU
08/06	Johnson & Johnson acquires Firefly Bio for 1 billion dollars and bets on breakthrough in KRAS cancer treatment	AQ
08/06	Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform	BU
03/06	Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study	PR
03/06	Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease	PR
31/05	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited	PR